SCHEMBL2608295

SCHEMBL2608295

C=C(C)C(=O)OCCCCNC(=O)/C=C/C(=O)OC(C)C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
ZDHHC20 Q5W0Z9 3/20 0.40
ZDHHC2 Q9UIJ5 3/20 0.40
HCAR2 Q8TDS4 1/20 0.37
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.35
APEX1 P27695 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
THRB P10828 1/20 0.35
ACHE P22303 6/20 0.31
ATM Q13315 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GFPT1 Q06210 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2608287 0.91 HCAR2 (0.40) TSHRZDHHC20ZDHHC2HCAR2MAPT
SCHEMBL10081656 0.87 TSHR (0.47) TSHRZDHHC20ZDHHC2HCAR2MAPT
SCHEMBL2608284 0.85 TSHR (0.51) TSHRHCAR2MAPTRAB9ANPSR1
SCHEMBL2608276 0.84 TSHR (0.47) TSHRZDHHC20ZDHHC2HCAR2MAPT
SCHEMBL12338864 0.84 ZDHHC20 (0.43) ZDHHC20ZDHHC2HCAR2MAPTRAB9A
SCHEMBL2608302 0.84 HCAR2 (0.41) ZDHHC20ZDHHC2HCAR2MAPTHTT
SCHEMBL2608286 0.82 HCAR2 (0.39) TSHRZDHHC20ZDHHC2HCAR2MAPT
SCHEMBL21115820 0.81 TSHR (0.50) TSHRMAPTPOLBAPEX1HTT
SCHEMBL2608262 0.80 ZDHHC20 (0.46) TSHRZDHHC20ZDHHC2HCAR2MAPT
SCHEMBL2608278 0.79 ZDHHC20 (0.51) TSHRZDHHC20ZDHHC2HCAR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345180-B2 Display medium for assessment and method for manufacturing same ZEON CORPORATION (JP) 2022-05-31 US disclosed
US-20190184732-A1 DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME ZEON CORPORATION (JP) 2019-06-20 US disclosed
US-8262931-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition, polymer and film FUJIFILM CORPORATION (JP) 2012-09-11 US disclosed
US-8158021-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article ZEON CORPORATION (JP) 2012-04-17 US disclosed
US-20110233464-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER AND FILM FUJIFILM CORPORATION (JP) 2011-09-29 US disclosed
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE ZEON CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE LEO1, ZYX, CCNT1 TSHR 4760/4885ZDHHC20 1156/4885ZDHHC2 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.